$HEIA (-2.16%)
$EL (+0.22%)
$NUE (-0.02%)
$CDNS (+2.6%)
$WM (-0.38%)
$MSFT (+0.63%)
$V (+0.08%)
$OR (-0.56%)
$AZN (+0.1%)
$MRK (+0.33%)
$PG (-0.4%)
$SBUX (+0.83%)
$BCS (+0%)
$META (+0.46%)
$BABA (+1.49%)
$QCOM (-0.49%)
$AIR (+0.19%)
$HSBC (+0.87%)
$GSK (-3.24%)
$MBG (+0.47%)
$F (+6.36%)
$AAPL (+1.23%)
$AMZN (+1.56%)
$MA (-0.34%)
$7203 (+0.82%)
$SHEL (-0.11%)
$005930
$SNY (+4.22%)
$CMCSA (-0.16%)
$COIN (+9.84%)
$NET (+0.22%)
$XOM (-0.4%)
$CVX (-0.65%)
$CS (+0.17%)
$NTDOY (-1.9%)
$CL (-0.97%)
$DTG (+0.81%)
$UNH (+1.21%)
- Markets
- Stocks
- Sanofi ADR Representing 1 1/2
- Forum Discussion
Discussion about SNY
Posts
2Quarterly figures 28.07-01.08

Sanofi reported earnings Q4 FY2024 results ended on December 31, 2024
- Revenue: €10.56B, +10.3% YoY at CER
- Net income: €683M vs -€555M in Q4 2023
- Business EPS: €1.31, -11.0% YoY at CER
- Full year revenue: €41.1B, +11.3% YoY at CER
CEO Paul Hudson: "We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with Beyfortus becoming a blockbuster in its first full year of sales."
🌱Revenue & Growth
- US sales: €5.15B, +13.3% YoY at CER
- Europe sales: €2.43B, +6.0% YoY at CER
- Rest of World: €2.98B, +8.8% YoY at CER
- Dupixent sales: €3.46B, +16.0% YoY at CER
- Vaccines sales: €2.18B, +10.8% YoY at CER
💰Profits & Financials
- Gross margin: 74.3%, -2.5pp YoY
- Business operating income: €2.08B, -7.7% YoY at CER
- Free cash flow: €2.34B, -25.5% YoY
- R&D expenses: €2.26B, +24.4% YoY
📌Business Highlights
- Received 14 regulatory approvals of medicines and vaccines in 2024
- Beyfortus achieved blockbuster status with €1.7B sales in first full year
- Plans to sell controlling stake in Opella consumer health business
🔮Future Outlook
- 2025 sales growth expected at mid-to-high single-digit percentage at CER
- Expects strong rebound in business EPS with low double-digit growth at CER
- Plans €5B share buyback program in 2025
- Dupixent sales expected to reach around €22B by 2030
Trending Securities
Top creators this week
